Multi-Agent Clinical Trial Matching: How a Pharma Consortium Cut Screening Time by 40%

The Consortium Pilot: Objectives, Scope, and Key Participants As of May 24, 2026, a consortium of 10 leading pharmaceutical firms and three academic medical centers completed a landmark 4-month pilot designed to automate patient matching for clinical trials. The objective was to reduce the manual, error-prone process of eligibility screening and site capacity matching—often cited as a major bottleneck in drug development. The pilot ran on AWS Bedrock and covered over 200 trial sites across therapeutic areas including oncology, cardiology, and rare diseases. Key participants included a major contract research organization (CRO) and a data integration partner specializing in healthcare interoperability. The consortium published its results via a joint technical report, marking the first known production-level multi-agent system in this regulated domain. Architecture Overview: Data Integrat

ion and Agent Orchestration on AWS Bedrock The system was built on a modular multi-agent architecture orchestrated through AWS Bedrock’s Agent collaboration framework. Two primary agent types handled distinct tasks: Eligibility Criteria Extraction Agent – ingests unstructured protocol documents (PDFs, site-specific amendments) and extracts structured eligibility rules. Site Capacity Matching Agent – processes real-time site availability, investigator schedules, and patient proximity to match candidates to enrolling sites. Data integration followed a hub-and-spoke pattern: a central FHIR-compatible data lake ingested electronic health record (EHR) snapshots, patient demographic data, and trial status feeds. Each agent subscribed to specific data streams via event-driven connectors, ensuring low-latency updates without direct database coupling. The orchestration layer maintained a shared s

tate graph to track patient progression through screening stages. Agent Roles: Eligibility Extraction with Qwen 3.8 Max and Site Capacity Matching with Llama 5 The Eligibility Extraction Agent used Qwen 3.8 Max (Alibaba Cloud) fine-tuned on a corpus of 50,000 de-identified clinical trial protocols and common eligibility rule patterns. Qwen’s strong performance on long-context understanding and multi-lingual medical terminology made it ideal for parsing unstructured inclusion/exclusion criteria. The consortium reported 92% accuracy in extracting binary eligibility rules (e.g., age, lab values) and 85% for complex logic (e.g., prior therapy combinations). The Site Capacity Matching Agent employed Llama 5 (Meta), chosen for its efficient inference and native function-calling abilities. Llama 5 was integrated with live APIs from trial management systems to query site capacity, investigator a

vailability, and patient travel distances. Its low latency (under 500ms per match) allowed the system to re-evaluate matches dynamically as new patients were enrolled or slots opened. Both agents were deployed in separate, encrypted containers on AWS Bedrock, with inference endpoints configured for strict HIPAA compliance (see next section). Ensuring HIPAA Compliance in a Multi-Agent Environment Maintaining HIPAA compliance across multiple autonomous agents required deliberate architectural decisions: Data Encryption : All patient data at rest and in transit used AES-256 and TLS 1.3. Agents could only access de-identified data subsets unless explicit patient consent was logged. Audit Logging : Every agent action, data access, and orchestration decision was logged in an immutable ledger. Logs included model input/output hashes to detect tampering. Role-Based Access : Only authenticated he

althcare professionals could trigger human-in-the-loop interventions. Agents had scoped permissions—e.g., the extraction agent could read protocol documents but not write to patient records. Model Guardrails : Custom guard rails on AWS Bedrock prevented agents from generating protected health information (PHI) in outputs. A secondary classifier screened all agent outputs for PHI leakage before any data moved back to the orchestration layer. The consortium passed an internal HIPAA audit prior to go-live and received a favorable preliminary review from an external compliance firm. Managing Probabilistic Model Failures: Hallucinations, Drift, and Escalation Paths Probabilistic models introduce failure modes unique to regulated environments. The consortium observed: Eligibility hallucinations : Qwen occasionally invented criteria (e.g., “patient must be on statin therapy” when missing from t

he protocol). Detection logic flagged outputs with low confidence (<80%) and escalated to a human reviewer. Model drift : Over 4 months, Llama 5’s site-match accuracy degraded by 3% due to changing site availability patterns. The team implemented weekly fine-tuning on fresh operational data and a sh